Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

NCT00364143 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: IHL-305 (irinotecan liposome injection)

Sponsor

Yakult Honsha Co., LTD